简介:目的:通过观察急性ST段抬高型心肌梗塞(STEMI)直接经皮冠状动脉介入治疗(PCI)术后,梗塞相关动脉(IRA)达心肌梗塞溶栓(TIMI)血流3级患者心电图ST段回落程度,探讨ST段回落与心肌损伤及心脏收缩功能的关系。方法:选择在发病12h内接受直接PCI治疗后TIMI血流达到3级的STEMI患者115例,PCI术前、术后行心电图检查,观察ST段回落情况,术前、后测定患者肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)及肌钙蛋白T(cTnT),术后测定左室射血分数(LVEF);按照ST段回落幅度(∑STR)不同,患者被分为两组:A组:∑STR〈50%,21例,为心肌灌注不良组,B组:∑STD≥50%,94例,为心肌灌注良好组;分析两组患者ST段回落程度与CK、CK-MB、cTnT及LVEF的关系。结果:(1)两组患者IRA部位、病变血管支数,PCI治疗前TIMI血流分级、cTnT水平,发病到PCI时间等差异均无显著性(P〉0.05);(2)两组患者术前、后CK、CK-MB水平差异无显著性(P〉0.05);(3)术后A组cTnT水平明显高于B组[(1.30±0.43)μg/L∶(1.0±0.45)μg/L,P〈0.05];(4)术后A组LVEF明显低于B组[(44.13±4.83)%∶(47.93±5.23)%,P〈0.05]。结论:急性ST段抬高型心肌梗塞直接PCI术后,TIMI血流达到3级,ST段回落良好的患者,心肌组织水平灌注程度较好,心肌损伤程度轻,左心收缩功能较好。
简介:目的探讨ST—T改变的鉴别方法及诊断意义。方法对210例患者除作心电图(ECG)外井做血生化(血脂、血糖、肝肾功能、心肌酶谱、甲状腺功能测定系列等)、超声心动图、心脏X线等检查,随机抽取54例行试验性治疗,即给予50%G.S250ml加复方丹参注射液20ml,生脉注射液100ml均1/d,10d。再规律休息1w后对比治疗前后ECG。结果54例治疗前后ECG比较无明显变化,并随访3—12个月无一例发生心脏事件,随机抽取32例ECG并做多帧前后比较差异无统计学意叉。结论本组病倒经临床检查排除药物影响、器质性心脏病及继发性心脏病。试验性治疗ST—T无改变,提示此组人群中ST—T改变为非特异性的。
简介:BackgroundNon-ST-segmentelevationacutecoronarysyndrome(NSTE-ACS)isanacuteheartdiseasecausedbyincompleteocclusionofrelatedcoronaryarterieswithunstableatheroscleroticplaques.LeadaVRSTsegmentelevationandcTnIpositivearecloselycorrelatedtotheprognosisofNSTE-ACSpatients.However,therearefewstudiesapplyingthetwopredictorstoearlyriskstratificationinNSTE-ACSpatients.MethodTwohundredandfivecasesofNSTE-ACSpatientsfollowedupfor6monthsafterdischargewerereviewed.Allpatientsweredividedintofourgroups:GroupA-cTnInegativecombinedwithaVR-non-ST-segmentelevationgroup(100cases);GroupB-cTnInegativecombinedwithaVR-ST-segmentelevationgroup(31cases);GroupC-cTnIpositivecombinedwithaVR-non-ST-segmentelevationgroup(43cases);GroupD-cTnIpositivecombinedwithaVR-ST-segmentelevationgroup(31cases).Therewasnosignificantdifferenceingender,age,oldmyocardialinfarction,previousPCIhistory,hypertension,anddiabetesbetweenaVR-STelevationgroupandnoaVR-STelevationgroup.Themorbidityofleftmainorthree-vesselcoronaryarterydiseaseaswellasadversecardiovasculareventsinthefourgroupswereobservedandanalyzed.Results(i)Themorbidityofleftmainorthree-vesselcoronaryarterydiseasewashighestinGroupD(87.1%),andwasmarkedlyhigherinGroupB(41.9%)thanthatinGroupA(7%)orGroupC(9.3%);(ii)TheincidenceofadversecardiovasculareventswashighestinGroupD(77.4%),andwasmuchhigherinB(35.5%)ascomparedwiththattinGroupA(1%)orgroupC(7%).ConclusionElectrocardiographicleadaVRST-segmentelevationcombinedwithcTnIpositivehasanimportantclinicalvalueinpredictingtheprognosisofthepatientswithNSTE-ACS.
简介:ObjectivesToexaminepatientdelay(PD)inseekingtreatmentamongpatientswithST-elevationmyocardialinfarction(STEMI)andtoidentifyfactorsinfluencingPD.MethodspatientswithSTEMIweredividedintotwogroupsbasedonPD:ShortPDgroup(PD≤60minutesafteronsetofsymptoms)andlongPDgroup(>60minutesaftersymptomonset).Aquestionnairedevelopedtoassessdemographiccharacteristics,clinicalfactorsandpsychologicalfactors.Patientswereinterviewedwithin72hoursofadmissionto2hospitals.Results329consecutiveconfirmedSTEMIpatients(Meanage61years;72.5%men)withamedianPDof90minandapre-hospitaldelaytime170minwerestudied,PDwaslessthan1hoursin47.4%ofpatients,whilemorethan1hoursin52.6%,Inunivariateanalyses,patientswithshortPDwerewitnessonset,progresscourseofsymptom,severepain,deathanxiety,knowingAMIasadeadlydiseaseanditspresentation,takingthesymptomseriously.PatientswithlongerPDwereage≥65year,nocturnalonset,experiencedtheirsymptomsathome,gradualonset,’waitedtoseewhethersymptomsdisappeared’,’worriedabouttroublingothers’,’tookpainmedication’andpreinfarctionangina.Astepwisemultipleregressionanalysisfurthersuggestedthatthefollowinginde-pendentcontributorstoalatedecisiontoseekmedicalhelp(relativerisk,95%confidenceinterval):takingpainmedication(15.97;1.70~149.8),wantingtowaitandsee(6.46;1.92~21.74),notwantingtobotheranybody(6.42;2.87~14.34),preinfarctangina(2.73;1.20~6.19),age≥65years(2.51;1.15~5.48),gradualonset(2.40;1.05~5.44),severepain(0.38,0.17~0.85),witnessonset(0.27,0.10~0.70),takingsymptomsseriously(0.019;0.08~0.46).ConclusionsAge≥65years,gradualonset,witnessonset,severepain,preinfarctangina,emotionalresponsesandcopingstrategiesaretheindependentfactorsassociatedwithpatientdelayordecisiontimeinpatientswithAMI.Emotionalresponsesandcopin
简介:Furtherunderstandingofthepathphophisyology,advanceofthediagnosisinstrumentandrenovationoftheriskdelaminationstandardcanofferbettertherapyevidenceforthenon-ST-segmentelevationacutecoronarysyndrome(NSTE-ACS).Drugs,suchastrigeminyantiplateletdrug,prasugrel,fondaparinuxandbivalirudin,havebroughtgreatclinicaleffecttothehighriskpatients.SincetheresultoftheICTUStestannouncedandthedrugelutingballoondeveloped,wehavereachedthenewestrecognitionofhowtoselectachanceforinterventionandhowtopreventandcuretherestenosisofin-stent.
简介:BackgroundThecombinationofglycoproteinⅡb/Ⅲainhibitorsandheparinhasnotbeencomparedwithbivalirudininstudiesspecificallyinvolvingpatientswithnon-ST-segmentelevationmyocardialinfarctionundergoingpercutaneouscoronaryintervention(PCI).Wecomparedthetwotreatmentsinthispatientpopulation.MethodsImmediatelybeforePCI,werandomlyassigned,inadouble-blindmanner,1721patientswithacutenon-ST-segmentelevationmyocardialinfarctiontoreceiveabciximabplusunfractionatedheparin(861patients)orbivalirudin(860patients).Thestudytestedthehypothesisthatabciximabandheparinwouldbesuperiortobivalirudinwithrespecttotheprimarycompositeendpointofdeath,largerecurrentmyocardialinfarction,urgenttarget-vesselrevascularization,ormajorbleedingwithin30days.Secondaryendpointsincludedthecompositeofdeath,anyrecurrentmyocardialinfarction,orurgenttarget-vesselrevascularization(efficacyendpoint)andmajorbleeding(safetyendpoint)within30days.ResultsTheprimaryendpointoccurredin10.9%ofthepatientsintheabciximabgroup(94patients)andin11.0%inthebivalirudingroup(95patients)(relativeriskwithabciximab,0.99;95%confidenceinterval[CI],0.74to1.32;P=0.94).Death,anyrecurrentmyocardialinfarction,orurgenttarget-vesselrevascularizationoccurredin12.8%ofthepatientsintheabciximabgroup(110patients)andin13.4%inthebivalirudingroup(115patients)(relativerisk,0.96;95%CI,0.74to1.25;P=0.76).Majorbleedingoccurredin4.6%ofthepatientsintheabciximabgroup(40patients)ascomparedwith2.6%inthebivalirudingroup(22patients)(relativerisk,1.84;95%CI,1.10to3.07;P=0.02).ConclusionsAbciximabandunfractionatedheparin,ascomparedwithbivalirudin,failedtoreducetherateoftheprimaryendpointandincreasedtheriskofbleedingamongpatientswithnon-ST-segmentelevationmyocardialinfarctionwhowereundergoingPCI.(FundedbyNycomedPharmaandothers;
简介:目的分析影响非ST段抬高心肌梗死(NSTEMI)预后的相关因素及有效的治疗策略。方眩收集2001年1月~2010年1月资料完整的NSTEMI患者206例,随访≥6个月,以随访6个月和2年的预后分别为近期和远期预后,记录心血管事件,包括主要终点事件(心源性死亡)和联合终点事件[心源性死亡和(或)非致死性心肌梗死],应用Cox生存模型对影响预后的多因素进行分析。结果142例完成6个月随访,共发生心血管事件20例,其中心源性死亡16例(11.27%)、非致死性心肌梗死4例(2.82%);93例完成2年随访,共发生心血管事件20例,其中心源性死亡15例(16.13%)、非致死性心肌梗死5例(5.38%)。影响患者班期预后的因素为年龄、心力衰竭、肾功能不全、阿司匹林,影响患者远期预后的因素为年龄、心力衰竭、肾功能不全、阿司匹林、早期PCI。结论NSTEMI患者预后不佳,年龄、心力衰竭、肾功能不全是最重要的危险因素,而阿司匹林是重要的保护因素,早期PCI可显著改善患者的远期预后。
简介:Toanalyzetheclinicalcharacteristicsof216patientswithnon-STsegmentelevationmyocardialinfarction(NSTEMI).MethodsAretrospectiveanalysiswasused.TwohundredandsixteenNSTEMIpatientsweredividedintotwogroups:①accordingtotheage:age<65yearsgroupandage≥65yearsgroup;②accordingtothrombolysisinmyocardialischemiatrial(TIMI)IIBriskstratificationscoringsystem:score<4groupand≥4group;③accordingtoserumcreatinine(sCr)level:sCrlevel≤178μmol·L-1groupand>178μmol·L-1group.Sevenhundredandeightysixacutemyocardialinfarction(AMI)patientsduringthesameperiodweredividedintoSTsegmentelevationmyocardialinfarction(STEMI)groupandNSTEMIgroup.Clinicalcharacteristicsofthepatientsinthetwogroupswerecompared.Results①ThenumberofNSTEMIpatientsinage≥65yearsgroupissignificantlygreaterthanthatinage<65yearsgroup.Studyrevealedthatthepatientsinage≥65yearsgroupwerewithoutchestpain,hadhypertension,dyslipidemia,atrialfibrillation,cardiacandrenaldysfunction(sCr>178μmol·L-1)andtriplevesseldisease.Fewerpatientsinthisgroupreceivedcoronaryarteryangiography(CAG),percutaneouscoronaryintervention(PCI)andcoronaryarterybypassgraft(CABG).Morenumberofdeathsinthisgroupcomparedwiththeage<65yearsgroup.②ThenumberofNSTEMIpatientsinTIMIscore>4groupissignificantlygreaterthanthatinTIMIscore<4group.Fourmajorcomplicationssuchasacuteleftventricularfailure,cardiogenicshock,seriousarrhythmiaanddeaths,increasedsignificantlyinTIMIscore>4groupcomparingwithTIMIscore≤4group.③Obviously,morenumberofelderlypatients,non-insulindependantdiabetesmellitus(NIDDM),patientswithcardiactroponinT(CTnT)>3.0ng·L-1anddeathsoccurredinsCr>178μmol·L-1group.④STEMIandNSTEMIpatientswerecomparedinsametimeframeasfollows:fewerNSTEMIpatientsandmoreelderlypatientshadnochestpain,NIDDM,hypert
简介:目的探讨急诊经皮冠脉介入术(PCI)治疗急性ST段抬高性心肌梗死(STEMI)患者术后ST段回落的临床意义。方法入选2011年1月~2013年9月辽宁省人民医院心血管内科急诊PCI治疗的150例STEMI患者进行回顾性分析,根据术后1h内患者心电图检查ST段回落百分比是否>50%分为A组84例(ST段回落百分比>50%)和B组66例(ST段回落百分比≤50%),比较两组患者术前、术后24h的心肌酶谱指标、术后2周心功能指标及术后1年内心血管不良事件的发生率。结果术前及术后24hA组的肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、肌钙蛋白(cTnT)测定值均显著的低于对应时间点的B组患者(P<0.05);术前,A、B两组患者的左室射血分数(LVEF)值差异不具有统计学意义(P>0.05),术后24h,A组患者LVEF值显著高于B组患者(P<0.05);术前及术后24hA组的左室舒张末期容积(LVEDV)测定值均显著的低于B组患者(P<0.05);术后1年A组患者的心血管不良事件累积发生率9.52%显著的低于B组患者的31.82%(P<0.05)。结论急诊PCI术后ST段迅速回落(ST段回落百分比>50%)的STEMI患者心功能及心肌酶谱指标恢复更好,远期不良心血管事件发生率更低。